Glycogen storage disease type II other imaging findings: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glycogen storage disease type II}} | {{Glycogen storage disease type II}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Anmol}} | ||
==Overview== | ==Overview== | ||
[[Dual energy X-ray absorptiometry]] ([[DXA]]) may be helpful in the diagnosis of [[osteoporosis]], [[osteopenia]], and/or fracture in patients with glycogen storage disease type 2. Findings on an [[dual energy X-ray absorptiometry]] suggestive of [[osteoporosis]] and/or [[osteopenia]] in patients with glycogen storage disease type 2 include low [[bone mineral density]] (BMD). | |||
[ | |||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* | ===Dual Energy X-ray Absorptiometry=== | ||
*[[Dual energy X-ray absorptiometry]] ([[DXA]]) may be helpful in the diagnosis of [[osteoporosis]], [[osteopenia]], and/or fracture in patients with glycogen storage disease type 2.<ref name="pmid16702877">{{cite journal| author=ACMG Work Group on Management of Pompe Disease. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ et al.| title=Pompe disease diagnosis and management guideline. | journal=Genet Med | year= 2006 | volume= 8 | issue= 5 | pages= 267-88 | pmid=16702877 | doi=10.109701.gim.0000218152.87434.f3 | pmc=3110959 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16702877 }} </ref> | |||
*[[Dual energy X-ray absorptiometry]] is used to diagnose low [[bone mineral density]] (BMD). | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 18:24, 17 January 2018
|
Glycogen storage disease type II Microchapters |
|
Differentiating Glycogen storage disease type II from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glycogen storage disease type II other imaging findings On the Web |
|
American Roentgen Ray Society Images of Glycogen storage disease type II other imaging findings |
|
FDA on Glycogen storage disease type II other imaging findings |
|
CDC on Glycogen storage disease type II other imaging findings |
|
Glycogen storage disease type II other imaging findings in the news |
|
Blogs on Glycogen storage disease type II other imaging findings |
|
Directions to Hospitals Treating Glycogen storage disease type II |
|
Risk calculators and risk factors for Glycogen storage disease type II other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Dual energy X-ray absorptiometry (DXA) may be helpful in the diagnosis of osteoporosis, osteopenia, and/or fracture in patients with glycogen storage disease type 2. Findings on an dual energy X-ray absorptiometry suggestive of osteoporosis and/or osteopenia in patients with glycogen storage disease type 2 include low bone mineral density (BMD).
Other Imaging Findings
Dual Energy X-ray Absorptiometry
- Dual energy X-ray absorptiometry (DXA) may be helpful in the diagnosis of osteoporosis, osteopenia, and/or fracture in patients with glycogen storage disease type 2.[1]
- Dual energy X-ray absorptiometry is used to diagnose low bone mineral density (BMD).
References
- ↑ ACMG Work Group on Management of Pompe Disease. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ; et al. (2006). "Pompe disease diagnosis and management guideline". Genet Med. 8 (5): 267–88. doi:10.109701.gim.0000218152.87434.f3 Check
|doi=value (help). PMC 3110959. PMID 16702877.